CAMBRIDGE, Mass., March 02, 2022 Generation Bio Co. , a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff. | March 2, 2022
24.02.2022 - Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people .
The Revita DMR System (Revita) gains reimbursement authorization from the German Institute for Hospital Remuneration (InEK) with a NUB Status 1 designation NUB Status 1 entitles participating
05.01.2022 - CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the .